Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 0.44 |
| ▸ | CNR2 | P34972 | 8/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839631 | 0.92 | CNR1 (0.51) | CNR1CNR2HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL1315433 | 0.91 | CNR1 (0.54) | CNR1CNR2HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4841351 | 0.91 | CNR1 (0.43) | CNR1CNR2HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4837890 | 0.89 | CNR1 (0.41) | CNR1CNR2HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4842366 | 0.87 | CNR1 (0.45) | CNR1CNR2 | |
| SCHEMBL4838030 | 0.87 | CNR1 (0.40) | CNR1CNR2HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4841160 | 0.86 | CNR1 (0.48) | CNR1CNR2ADORA2AADORA2BADORA1 | |
| SCHEMBL27782956 | 0.85 | CNR1 (0.36) | CNR1CNR2HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4843477 | 0.84 | CNR1 (0.49) | CNR1CNR2HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4842356 | 0.84 | CNR1 (0.47) | CNR1CNR2HPGDALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101583593-A | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | PFIZER PROD INC (US) | 2009-11-18 | — | — | CN | claimed |
| EP-2084127-A1 | DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-08-05 | — | — | EP | claimed |
| EP-2064199-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008059335-A1 | DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-05-22 | — | — | WO | claimed |
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | PFIZER INC | 2008-03-20 | — | — | US | claimed |
| WO-2008032156-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | claimed |
| EP-1890767-A2 | COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS | Pfizer Products Inc. (US) | 2008-02-27 | — | — | EP | claimed |
| US-7329658-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2008-02-12 | — | — | US | claimed |
| WO-2007039797-A1 | USE OF CANNABINOID RECEPTOR-1 ANTAGONIST FOR TREATING INFLAMMATION AND ARTHRITIS | PFIZER PRODUCTS INC. (US) | 2007-04-12 | — | — | WO | claimed |
| JP-2007502808-A | — | — | 2007-02-15 | — | — | JP | claimed |
| WO-2006129193-A2 | COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2006-12-07 | — | — | WO | claimed |
| US-20060270655-A1 | Combination therapy for treating obesity or maintaining weight loss | SWICK ANDREW G | 2006-11-30 | — | — | US | claimed |
| EP-1658082-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1626738-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| WO-2005018645-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043327-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| WO-2004098641-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| US-20040224963-A1 | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal | PFIZER INC | 2004-11-11 | — | — | US | claimed |
| US-20040224962-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2004-11-11 | — | — | US | claimed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | CNR1 13/4885CNR2 20/4885HPGD 1256/4885 |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885HPGD 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.